<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248364</url>
  </required_header>
  <id_info>
    <org_study_id>1245.39</org_study_id>
    <secondary_id>2010-018708-99</secondary_id>
    <nct_id>NCT01248364</nct_id>
  </id_info>
  <brief_title>A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects</brief_title>
  <official_title>An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postprandial Glucose Homeostasis in Patients With IGT and, Type 2 Diabetes Mellitus and Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI
      10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2
      diabetes mellitus and assess the acute effects of empagliflozin in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Day 1</measure>
    <time_frame>Baseline and day 1</time_frame>
    <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Day 28</measure>
    <time_frame>Baseline and day 28</time_frame>
    <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 28.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1</time_frame>
    <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28</time_frame>
    <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 1</measure>
    <time_frame>Baseline and day 1</time_frame>
    <description>Change from baseline in rate of endogenous glucose production (EGP) fast after one dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 28</measure>
    <time_frame>Baseline and day 28</time_frame>
    <description>Change from baseline in rate of endogenous glucose production (EGP) fast after 28 days of treatment.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 1</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1</time_frame>
    <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 28</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28</time_frame>
    <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 1</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 1</time_frame>
    <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28</measure>
    <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 28</time_frame>
    <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 high dose once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets once daily high dose</description>
    <arm_group_label>BI 10773 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients diagnosed with IGT according to the current ADA guidelines as
             a two-hour glucose levels of 140 to 199 mg/dl (7.8 mmol/l to 11.1 mmol/l) on the 75-g
             oral glucose tolerance test (OGTT), with an OGTT performed at the time of the
             screening visit (Visit 1), or

             ¿ Male and female patients diagnosed with type 2 diabetes mellitus (T2DM) prior to
             informed consent, on diet and exercise regimen who are drug-naïve, defined as absence
             of any oral antihyperglycemic therapy for 12 weeks prior starting with open-label
             active treatment, or

          2. Male and female patients diagnosed with type 2 diabetes mellitus prior to informed
             consent, who are pre-treated with metformin background therapy, on a stable dose of
             metformin of at least 1500 mg per day, unchanged for at least 12 weeks prior starting
             with open-label active treatment

          3. HbA1c at Visit 1 (screening)

               1. for patients diagnosed of IGT and for healthy subjects: HbA1c &lt; 6.5%

               2. for patients diagnosed of T2DM: HbA1c =6.5% and =10.5%

          4. Age = 18 at Visit 1

          5. BMI = 20 and = 40 Kg/m2 at Visit 1

          6. For patients with antihypertensive treatment, this must be stable (with no change in
             dosage) within 4 weeks prior starting with open-label active treatment

          7. Signed and dated written informed consent by date of Visit 1 in accordance with GCP
             and local legislation

             Inclusion criteria for healthy subjects:

          8. Males or females matching the below mentioned criteria and otherwise healthy according
             to the investigator¿s assessment, as based on the following criteria: a complete
             medical history including a physical examination, vital signs (BP, PR) and clinical
             laboratory tests .

          9. HbA1c at Visit 1 (screening): HbA1c &lt; 6.5%

         10. Confirmed normal glucose tolerance (NGT) by OGTT

         11. Age = 45 and = 55 at Visit 1.

         12. BMI = 30 and = 40 Kg/m2 (Body Mass Index) at Visit 1.

         13. Signed and dated written informed consent by date of Visit 1 in accordance with GCP
             and local legislation.

        Exclusion criteria:

          1. Acute coronary syndrome (non-STEMI [ST elevation myocardial infarction], STEMI,
             unstable AP [angina pectoris]), stroke or Transient Ischemic Attack (TIA) within 6
             months prior to informed consent.

          2. Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/L) after an
             overnight fast during placebo run-in and confirmed by a second measurement (not on the
             same day).

          3. Any other antidiabetic drug within 12 weeks prior to starting the open-label active
             treatment (Visit 4) except those defined as background via inclusion criterion 1c.

          4. Indication of liver disease, defined by serum levels of either Alanine
             Aminotransferase (ALT [SGPT]), Aspartate Aminotransferase (AST [SGOT]), or alkaline
             phosphatase above 3 x upper limit of normal (ULN) as determined during screening
             and/or run-in phase.

          5. Impaired renal function, defined as estimated Glomerular Filtration Rate (eGFR) &lt; 60
             ml/min (moderate and severe renal impairment) as determined during screening and/or
             run-in phase.

          6. Medical history of insufficient bladder emptying (i.e. neurogenic bladder disorders).

          7. Patients with an Haemoglobin (Hb) &lt; 11.5 g/dl (for males) and Hb &lt; 10.5 g/dl (for
             females) at Visit 1.

          8. Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption within the last 5 years.

          9. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years.

         10. For patients on metformin background therapy, the investigator must check for
             potential exclusion criteria according to local metformin label.

         11. Treatment with anti-obesity drugs 3 months prior to informed consent or any other
             treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.)
             leading to unstable body weight.

         12. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except T2DM. However, the use of inhaled steroids
             (e.g., for asthma, Chronic Obstructive Pulmonary Disease [COPD]) is not an exclusion
             as these do not cause systemic steroid action.

         13. Alcohol or drug abuse (according to investigators judgment) within the 3 months prior
             to informed consent that would interfere with trial participation or any ongoing
             condition leading to a decreased compliance to study procedures or study drug intake.

         14. Intake of an investigational drug in another trial Participation in another trial
             within 30 days prior to intake of study medication in this trial.

         15. Pre-menopausal women (last menstruation &lt; = 1 year prior to informed consent) who:

             Are nursing or pregnant or Are of child-bearing potential and are not practicing an
             acceptable method of birth control, or do not plan to continue using this method
             throughout the study and do not agree to submit to periodic pregnancy testing during
             participation in the trial.

         16. Any other clinical condition that would jeopardize patients safety while participating
             in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.39.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.39.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.39.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>August 29, 2014</results_first_submitted>
  <results_first_submitted_qc>August 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <disposition_first_submitted>April 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 14, 2014</disposition_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>T2DM Naive</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>T2DM Metformin</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Impaired Glucose Tolerance</title>
          <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Healthy Subjects</title>
          <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Acute Phase:Single Dose, Day 1</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Chronic Phase:28-day Treatment</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all patients/healthy subjects treated with at least one dose of empagliflozin.</population>
      <group_list>
        <group group_id="B1">
          <title>T2DM Naive</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>T2DM Metformin</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Impaired Glucose Tolerance</title>
          <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Healthy Subjects</title>
          <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="7.0"/>
                    <measurement group_id="B2" value="63.3" spread="6.5"/>
                    <measurement group_id="B3" value="50.8" spread="9.8"/>
                    <measurement group_id="B4" value="47.7" spread="2.3"/>
                    <measurement group_id="B5" value="58.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Day 1</title>
        <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 1</description>
        <time_frame>Baseline and day 1</time_frame>
        <population>Treated set which included all patients/healthy subjects with at least one dose of empagliflozin (original result (OR))</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Day 1</title>
          <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 1</description>
          <population>Treated set which included all patients/healthy subjects with at least one dose of empagliflozin (original result (OR))</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.12"/>
                    <measurement group_id="O2" value="0.39" spread="0.13"/>
                    <measurement group_id="O3" value="-0.96" spread="0.86"/>
                    <measurement group_id="O4" value="-0.47" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2790</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline FPG, diagnosis group, and baseline FPG by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Day 28</title>
        <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 28.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable</description>
        <time_frame>Baseline and day 28</time_frame>
        <population>Treated set, which included all patients/healthy subjects with at least one dose of empagliflozin (original result (OR)), for patients who completed the day 28 visit</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Day 28</title>
          <description>Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 28.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable</description>
          <population>Treated set, which included all patients/healthy subjects with at least one dose of empagliflozin (original result (OR)), for patients who completed the day 28 visit</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.13"/>
                    <measurement group_id="O2" value="-0.79" spread="0.15"/>
                    <measurement group_id="O3" value="-0.81" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2438</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline FPG, diagnosis group and baseline FPG by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 1</title>
        <description>Change from baseline in rate of endogenous glucose production (EGP) fast after one dose</description>
        <time_frame>Baseline and day 1</time_frame>
        <population>Treated set (OR)</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 1</title>
          <description>Change from baseline in rate of endogenous glucose production (EGP) fast after one dose</description>
          <population>Treated set (OR)</population>
          <units>umol/kgFFM/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="0.45"/>
                    <measurement group_id="O2" value="4.51" spread="0.60"/>
                    <measurement group_id="O3" value="3.28" spread="0.89"/>
                    <measurement group_id="O4" value="1.10" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6931</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG fast, diagnosis group and baseline EPG fast by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 28</title>
        <description>Change from baseline in rate of endogenous glucose production (EGP) fast after 28 days of treatment.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
        <time_frame>Baseline and day 28</time_frame>
        <population>Treated set (OR) for patients who completed the day 28 visit</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 28</title>
          <description>Change from baseline in rate of endogenous glucose production (EGP) fast after 28 days of treatment.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
          <population>Treated set (OR) for patients who completed the day 28 visit</population>
          <units>umol/kgFFM/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.71"/>
                    <measurement group_id="O2" value="4.63" spread="0.86"/>
                    <measurement group_id="O3" value="1.47" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1028</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG fast, diagnosis group and baseline EPG fast by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 1</title>
        <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1</time_frame>
        <population>Treated set (OR)</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 1</title>
          <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.</description>
          <population>Treated set (OR)</population>
          <units>g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="1.80"/>
                    <measurement group_id="O2" value="8.76" spread="1.77"/>
                    <measurement group_id="O3" value="3.70" spread="2.73"/>
                    <measurement group_id="O4" value="9.22" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0326</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG AUC 5h, diagnosis group and baseline EPG AUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>10.50</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1</title>
        <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1</time_frame>
        <population>Treated set (OR)</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1</title>
          <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.</description>
          <population>Treated set (OR)</population>
          <units>g/dL/h</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="0.53"/>
                    <measurement group_id="O2" value="-3.52" spread="0.61"/>
                    <measurement group_id="O3" value="-5.49" spread="1.95"/>
                    <measurement group_id="O4" value="-9.20" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0552</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline PPG iAUC 5h, diagnosis group and baseline PPG iAUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28</title>
        <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28</time_frame>
        <population>Treated set (OR) for patients who completed the day 28 visit</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28</title>
          <description>Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
          <population>Treated set (OR) for patients who completed the day 28 visit</population>
          <units>g/dL/h</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.67"/>
                    <measurement group_id="O2" value="-0.40" spread="0.72"/>
                    <measurement group_id="O3" value="-7.31" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7561</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline PPG iAUC 5h, diagnosis group and baseline PPG iAUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 28</title>
        <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28</time_frame>
        <population>Treated set (OR) for patients who completed the day 28 visit</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 28</title>
          <description>Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
          <population>Treated set (OR) for patients who completed the day 28 visit</population>
          <units>g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.35"/>
                    <measurement group_id="O2" value="5.02" spread="1.33"/>
                    <measurement group_id="O3" value="3.14" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1024</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG AUC 5h, diagnosis group and baseline EPG AUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>6.90</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 1</title>
        <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 1</time_frame>
        <population>Treated set (OR)</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 1</title>
          <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.</description>
          <population>Treated set (OR)</population>
          <units>g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.52" spread="1.79"/>
                    <measurement group_id="O2" value="-7.22" spread="2.33"/>
                    <measurement group_id="O3" value="-3.75" spread="3.82"/>
                    <measurement group_id="O4" value="1.28" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6576</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG iAUC 5h, diagnosis group and baseline EPG iAUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.93</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.53</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28</title>
        <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
        <time_frame>0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 28</time_frame>
        <population>Treated set (OR) for patients who completed the day 28 visit</population>
        <group_list>
          <group group_id="O1">
            <title>T2DM Naive</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>T2DM Metformin</title>
            <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Impaired Glucose Tolerance</title>
            <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Healthy Subjects</title>
            <description>Healthy subjects received a single dose of empagliflozin (empa) 25mg, in tablet form.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28</title>
          <description>Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.
Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable.</description>
          <population>Treated set (OR) for patients who completed the day 28 visit</population>
          <units>g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.95" spread="2.26"/>
                    <measurement group_id="O2" value="-10.63" spread="2.50"/>
                    <measurement group_id="O3" value="-0.49" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, exploratory analysis only.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2795</p_value>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline EPG iAUC 5h, diagnosis group and baseline EPG iAUC 5h by diagnosis group interaction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.41</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
            <estimate_desc>Difference calculated as T2DM metformin minus T2DM Naive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first intake of study drug until 7 days after the last treatment intake, 5 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T2DM Naive</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who have not been treated with any antihyperglycemic therapy for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>T2DM Metformin</title>
          <description>Patients diagnosed with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin of at least 1500 mg per day, for the last 12 weeks prior to the study. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Impaired Glucose Tolerance</title>
          <description>Patients diagnosed with impaired glucose tolerance (IGT) according to American Diabetes Association (ADA) guidelines. Patients received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Healthy Subjects</title>
          <description>Healthy subjects received empagliflozin (empa) 25mg tablet once daily for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

